Human Gene Set: MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_BCG_PRIMED_28DY_UP

GSEA and MSigDB Need Your Support

We are preparing a grant proposal to NCI's Information Technology for Cancer Research program for the continued funding of GSEA and MSigDB. Click here to learn how you can help. (show)


Standard name MATSUMIYA_PBMC_MODIFIED_VACCINIA_ANKARA_VACCINE_AGE_4_6MO_BCG_PRIMED_28DY_UP
Systematic name M41004
Brief description Genes up-regulated in peripheral blood mononuclear cell 28d vs 7d in infants (4-6m) (BCG-primed) after exposure to Modified Vaccinia Ankara (MVA) virus vaccine vector , time point 28D
Full description or abstract BACKGROUND: Tuberculosis (TB) remains a global health problem, with vaccination likely to be a necessary part of a successful control strategy. Results of the first Phase 2b efficacy trial of a candidate vaccine, MVA85A, evaluated in BCG-vaccinated infants were published last year. Although no improvement in efficacy above BCG alone was seen, cryopreserved samples from this trial provide an opportunity to study the immune response to vaccination in this population. METHODS: We investigated blood samples taken before vaccination (baseline) and one and 28 days post-vaccination with MVA85A or placebo (Candin). The IFN-gamma ELISpot assay was performed at baseline and on day 28 to quantify the adaptive response to Ag85A peptides. Gene expression analysis was performed at all three timepoints to identify early gene signatures predictive of the magnitude of the subsequent adaptive T cell response using the significance analysis of microarrays (SAM) statistical package and gene set enrichment analysis. RESULTS: One day post-MVA85A, there is an induction of inflammatory pathways compared to placebo samples. Modules associated with myeloid cells and inflammation pre- and one day post-MVA85A correlate with a higher IFN-gamma ELISpot response post-vaccination. By contrast, previous work done in UK adults shows early inflammation in this population is not associated with a strong T cell response but that induction of regulatory pathways inversely correlates with the magnitude of the T cell response. This may be indicative of important mechanistic differences in how T cell responses develop in these two populations following vaccination with MVA85A. CONCLUSION: The results suggest the capacity of MVA85A to induce a strong innate response is key to the initiation of an adaptive immune response in South African infants but induction of regulatory pathways may be more important in UK adults. Understanding differences in immune response to vaccination between populations is likely to be an important aspect of developing successful vaccines and vaccination strategies. TRIAL: ClinicalTrials.gov number NCT00953927.
Collection C7: Immunologic Signature
      VAX: HIPC Vaccine Response
Source publication Pubmed 24912498   Authors: Matsumiya M,Harris SA,Satti I,Stockdale L,Tanner R,O'Shea MK,Tameris M,Mahomed H,Hatherill M,Scriba TJ,Hanekom WA,McShane H,Fletcher HA
Exact source Table 3
Related gene sets (show 3 additional gene sets from the source publication)

(show 25 gene sets from the same authors)
External links https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061512/table/T3/
Filtered by similarity ?
Organism Homo sapiens
Contributed by HIPC SIGNATURES (NIAID/HIPC SIGNATURES)
Source platform HUMAN_GENE_SYMBOL
Dataset references  
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 10 genes
Gene families ? Categorize these 10 genes by gene family
Show members (show 10 members mapped to 10 genes)
Version history 7.3: First Introduced.

See MSigDB license terms here. Please note that certain gene sets have special access terms.